Project 05 · 2026–2027 · In progress

Proving EVA against
today's methods.

With the science established across the first four projects, EVA is measured against the world it aims to change: the sperm-selection methods clinics rely on today, in real commercial conditions.

Project insight

Decision-grade evidence, not bench results.

The aim is comparative evidence: how EVA's self-selected sperm subpopulation performs beside conventional techniques on the outcomes embryologists actually care about, and how it fits the day-to-day reality of a working laboratory.

Head-to-head comparison

EVA is benchmarked directly against the conventional techniques a clinic already uses, not evaluated in isolation.

Real commercial conditions

Run in a working lab's actual day-to-day, not a controlled research setting, so the evidence reflects real adoption conditions.

Why it matters

Closing the loop to adoption.

Building on the first Rennes-Saint-Malo Experimentation, RSM II closes the loop from biological proof to competitive, market-facing validation. This is the evidence that turns clinical interest into clinical adoption, the case a fertility centre needs before it changes how it selects sperm.

iProject info
Period
2026–2027
Programme
La French Tech Rennes Saint-Malo
Focus
Comparative validation
Keywords
Comparative validation, commercial-conditions evidence, clinical adoption
Comparative validation
Mr. Omar SaubryMr. Omar SaubryR&D Engineer Dr. Arnaud MauryDr. Arnaud MauryR&D Project Manager Dr. Shiva Kant ShuklaDr. Shiva Kant ShuklaPrincipal Investigator
Dissemination

Funded by La French Tech Rennes Saint-Malo.

Results will feed directly into the evidence base clinics and partners use to evaluate EVA for routine adoption.

← Back to projects